Overview

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
Phase:
Phase 1
Details
Lead Sponsor:
Escient Pharmaceuticals, Inc